AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Rheumatoid arthritis (RA) is a relatively common inflammatory disease that affects the synovial tissue, eventually results in joints destruction and even long-term disability. Although Janus kinase inhibitors (Jakinibs) show a rapid efficacy and are becoming the most successful agents in RA therapy, high dosing at frequent interval and severe toxicities cannot be avoided. Here, we developed a new type of fully compatible nanocarriers based on recombinant chimeric proteins with outstanding controlled release of upadacitinib. In addition, the fluorescent protein component of the nanocarriers enabled noninvasive fluorescence imaging of RA lesions, thus allowing real-time detection of RA therapy. Using rat models, the nanotherapeutic is shown to be superior to free upadacitinib, as indicated by extended circulation time and sustained bioefficacy. Strikingly, this nanosystem possesses an ultralong half-life of 45 h and a bioavailability of 4-times higher than pristine upadacitinib, thus extending the dosing interval from one day to 2 weeks. Side effects such as over-immunosuppression and leukocyte levels reduction were significantly mitigated. This smart strategy boosts efficacy, safety and visuality of Jakinibs in RA therapy, and potently enables customized designs of nanoplatforms for other therapeutics.
Smolen, J. S.; Aletaha, D.; McInnes, I. B. Rheumatoid arthritis. Lancet 2016, 388, 2023–2038.
Figus, F. A.; Piga, M.; Azzolin, I.; McConnell, R.; Iagnocco, A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun. Rev. 2021, 20, 102776.
Newsom, M.; Bashyam, A. M.; Balogh, E. A.; Feldman, S. R.; Strowd, L. C. New and emerging systemic treatments for atopic dermatitis. Drugs 2020, 80, 1041–1052.
Baker, K. F.; Isaacs, J. D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis. . Ann. Rheum. Dis. 2018, 77, 175–187.
Schwartz, D. M.; Kanno, Y.; Villarino, A.; Ward, M.; Gadina, M.; O’Shea, J. J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat. Rev. Drug Discov. 2017, 16, 843–862.
Damsky, W.; Peterson, D.; Ramseier, J.; Al-Bawardy, B.; Chun, H.; Proctor, D.; Strand, V.; Flavell, R. A.; King, B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J. Allergy Clin. Immunol. 2021, 147, 814–826.
Serhal, L.; Edwards, C. J. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol. 2019, 15, 13–25.
Malemud, C. J. The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther. Adv. Musculoskelet. Dis. 2018, 10, 117–127.
Burmester, G. R.; Kremer, J. M.; Van Den Bosch, F.; Kivitz, A.; Bessette, L.; Li, Y. H.; Zhou, Y. J.; Othman, A. A.; Pangan, A. L.; Camp, H. S. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018, 391, 2503–2512.
Fang, Y.; Xue, J. X.; Gao, S.; Lu, A. Q.; Yang, D. J.; Jiang, H.; He, Y.; Shi, K. Cleavable PEGylation: A strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Deliv. 2017, 24, 22–32.
Li, Y. X.; Sun, J.; Li, J. J.; Liu, K.; Zhang, H. J. Engineered protein nanodrug as an emerging therapeutic tool. Nano Res. 2022, 15, 5161–5172.
Talkington, A. M.; McSweeney, M. D.; Zhang, T.; Li, Z. B.; Nyborg, A. C.; LaMoreaux, B.; Livingston, E. W.; Frank, J. E.; Yuan, H.; Lai, S. K. High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies. J. Control. Release 2021, 338, 804–812.
Yousefpour, P.; Ahn, L.; Tewksbury, J.; Saha, S.; Costa, S. A.; Bellucci, J. J.; Li, X. H.; Chilkoti, A. Conjugate of doxorubicin to albumin-binding peptide outperforms aldoxorubicin. Small 2019, 15, 1804452.
Larsen, M. T.; Kuhlmann, M.; Hvam, M. L.; Howard, K. A. Albumin-based drug delivery: Harnessing nature to cure disease. Mol. Cell. Ther. 2016, 4, 3.
Zhang, N.; Mei, K.; Guan, P.; Hu, X. L.; Zhao, Y. L. Protein-based artificial nanosystems in cancer therapy. Small 2020, 16, 1907256.
Raveendran, S.; Sen, A.; Maekawa, T.; Kumar, D. S. Three-dimensional visualization of subcellular dynamics of cancer cell destruction on therapeutic nanodrug treatment. Small Struct. 2021, 2, 2000145.
Chang, R.; Yan, X. H. Supramolecular immunotherapy of cancer based on the self-assembling peptide design. Small Struct. 2020, 1, 2000068.
Rauf, M. A.; Tasleem, M.; Bhise, K.; Tatiparti, K.; Sau, S.; Iyer, A. K. Nano-therapeutic strategies to target coronavirus. View 2021, 2, 20200155.
Wang, C. Y.; Zhang, J. R.; Li, B.; Zuo, J. L.; Li, Y. X.; Sun, Y.; Wang, F.; Liu, K.; Li, J. J. High-efficiency treatment for osteoarthritis via self-assembled dual-functionalized nanobiologics. ACS Biomater. Sci. Eng. 2022, 8, 3320–3328.
Wan, S. K.; Cheng, W. H.; Li, J. J.; Wang, F.; Xing, X. W.; Sun, J.; Zhang, H. J.; Liu, K. Biological composite fibers with extraordinary mechanical strength and toughness mediated by multiple intermolecular interacting networks. Nano Res. 2022, 15, 9192–9198.
Sun, J.; Chen, J. S.; Liu, K.; Zeng, H. B. Mechanically strong proteinaceous fibers: Engineered fabrication by microfluidics. Engineering 2021, 7, 615–623.
Sun, J.; Li, B.; Wang, F.; Feng, J.; Ma, C.; Liu, K.; Zhang, H. J. Proteinaceous fibers with outstanding mechanical properties manipulated by supramolecular interactions. CCS Chem. 2020, 3, 1669–1677.
Haller, J.; Hyde, D.; Deliolanis, N.; De Kleine, R.; Niedre, M.; Ntziachristos, V. Visualization of pulmonary inflammation using noninvasive fluorescence molecular imaging. J. Appl. Physiol. 2008, 104, 795–802.
Put, S.; Westhovens, R.; Lahoutte, T.; Matthys, P. Molecular imaging of rheumatoid arthritis: Emerging markers, tools, and techniques. Arthritis Res. Ther. 2014, 16, 208.
Lee, J. H.; Jung, S. Y.; Park, G. K.; Bao, K.; Hyun, H.; El Fakhri, G.; Choi, H. S. Fluorometric imaging for early diagnosis and prognosis of rheumatoid arthritis. Adv. Sci. 2020, 7, 1902267.
Li, J. J.; Li, B.; Sun, J.; Ma, C.; Wan, S. K.; Li, Y. X.; Göstl, R.; Herrmann, A.; Liu, K.; Zhang, H. J. Engineered near-infrared fluorescent protein assemblies for robust bioimaging and therapeutic applications. Adv. Mater. 2020, 32, 2000964.
Ma, C.; Sun, J.; Li, B.; Feng, Y.; Sun, Y.; Xiang, L.; Wu, B. H.; Xiao, L. L.; Liu, B. M.; Petrovskii, V. S. et al. Ultra-strong bio-glue from genetically engineered polypeptides. Nat. Commun. 2021, 12, 3613.
Wang, Z. L.; Gu, X. Q.; Li, B.; Li, J. J.; Wang, F.; Sun, J.; Zhang, H. J.; Liu, K.; Guo, W. S. Molecularly engineered protein glues with superior adhesion performance. Adv. Mater. 2022, 34, 2204590.
Ma, C.; Li, B.; Zhang, J. R.; Sun, Y.; Li, J. J.; Zhou, H. C.; Shen, J. L.; Gu, R.; Qian, J. C.; Fan, C. H. et al. Significantly improving the bioefficacy for rheumatoid arthritis with supramolecular nanoformulations. Adv. Mater. 2021, 33, 2100098.
Li, J. J.; Sun, Y.; Liang, Y. X.; Ma, J.; Li, B.; Ma, C.; Tanzi, R. E.; Zhang, H. J.; Liu, K.; Zhang, C. Extracellular elastin molecule modulates Alzheimer’s Aβ dynamics in vitro and in vivo by affecting microglial activities. CCS Chem. 2021, 3, 1830–1837.
Wang, S. D.; Li, B.; Zhang, H. L.; Chen, J. Y.; Sun, X.; Xu, J.; Ren, T. T.; Zhang, Y. Y.; Ma, C.; Guo, W. et al. Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment. Angew. Chem., Int. Ed. 2021, 60, 11252–11256.
Su, J. J.; Lu, S.; Jiang, S. J.; Li, B.; Liu, B.; Sun, Q. N.; Li, J. J.; Wang, F.; Wei, Y. Engineered protein photo-thermal hydrogels for outstanding in situ tongue cancer therapy. Adv. Mater. 2021, 33, 2100619.
Wu, C. H.; Zhao, W. W.; Zhang, X. N.; Chen, X. P. Neocryptotanshinone inhibits lipopolysaccharide-induced inflammation in RAW264.7 macrophages by suppression of NF-κB and INOS signaling pathways. Acta Pharm. Sin. B 2015, 5, 323–329.
Xu, N. L.; Wang, Y. J.; Zhao, S.; Jiao, T.; Xue, H. X.; Shan, F. P.; Zhang, N. Naltrexone (NTX) relieves inflammation in the collagen-induced- arthritis (CIA) rat models through regulating TLR4/NFκB signaling pathway. Int. Immunopharmacol. 2020, 79, 106056.
